REDUCE-IT™ Cardiovascular Outcomes Study of Vascepa® (icosapent ethyl) Capsules Met Primary Endpoint Submitted by amarin on Mon, 09/24/2018 - 08:31 Home Read more about REDUCE-IT™ Cardiovascular Outcomes Study of Vascepa® (icosapent ethyl) Capsules Met Primary Endpoint
REDUCE-IT™ Trial Primary Results Accepted for Presentation at 2018 Scientific Sessions of American Heart Association Submitted by amarin on Wed, 09/12/2018 - 13:22 Home Read more about REDUCE-IT™ Trial Primary Results Accepted for Presentation at 2018 Scientific Sessions of American Heart Association
Amarin’s REDUCE-IT™ Clinical Study Now Positioned to be Next Large Cardiovascular Outcomes Study to Report Results Submitted by amarin on Sun, 08/26/2018 - 15:02 Home Read more about Amarin’s REDUCE-IT™ Clinical Study Now Positioned to be Next Large Cardiovascular Outcomes Study to Report Results
Real-World Data Supports Association Between Elevated Triglyceride Levels and Increased Peripheral Arterial Revascularization in High Risk Statin-Treated Patients Submitted by amarin on Sat, 08/25/2018 - 09:02 Home Read more about Real-World Data Supports Association Between Elevated Triglyceride Levels and Increased Peripheral Arterial Revascularization in High Risk Statin-Treated Patients
Report of unscheduled material events or corporate event Submitted by amarin on Wed, 08/01/2018 - 10:51 Home Read more about Report of unscheduled material events or corporate event
Quarterly report which provides a continuing view of a company's financial position Submitted by amarin on Wed, 08/01/2018 - 10:51 Home Read more about Quarterly report which provides a continuing view of a company's financial position
Amarin Reports Second Quarter 2018 Financial Results and Provides Update on Operations Submitted by amarin on Wed, 08/01/2018 - 09:01 Home Read more about Amarin Reports Second Quarter 2018 Financial Results and Provides Update on Operations
Amarin Announces Approval for Vascepa® in United Arab Emirates Submitted by amarin on Thu, 07/26/2018 - 12:51 Home Read more about Amarin Announces Approval for Vascepa® in United Arab Emirates
Amarin to Report Second Quarter 2018 Results and Host Conference Call on August 1, 2018 Submitted by amarin on Tue, 07/24/2018 - 09:01 Home Read more about Amarin to Report Second Quarter 2018 Results and Host Conference Call on August 1, 2018
Statement of changes in beneficial ownership of securities Submitted by amarin on Tue, 07/03/2018 - 20:21 Home Read more about Statement of changes in beneficial ownership of securities
